Tactile Systems Technology Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 4/6
Tactile Systems Technology verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 41.7%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 10.1%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 10.7%. Die Eigenkapitalrendite von Tactile Systems Technology beträgt 8.7% und die Nettomargen betragen 5.8%.
Wichtige Informationen
41.69%
Wachstumsrate der Gewinne
40.25%
EPS-Wachstumsrate
| Medical Equipment Wachstum der Industrie | 8.90% |
| Wachstumsrate der Einnahmen | 10.70% |
| Eigenkapitalrendite | 8.72% |
| Netto-Marge | 5.79% |
| Nächste Ertragsaktualisierung | 04 May 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
TCMD: Lymphedema Execution And Multi Year Guidance Will Support Continued Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to around $38, supported by higher projections for revenue growth, improved profit margins, and a lower assumed future P/E multiple following recent Q4 upside and updated multi year guidance. Analyst Commentary Recent Street research on Tactile Systems Technology highlights a range of views on execution, growth prospects, and valuation following the Q4 results and updated multi year guidance.Should You Think About Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD) Now?
Apr 18
TCMD: Lymphedema Momentum And Q4 Execution Will Drive Multi Year Upside
The updated analyst price target for Tactile Systems Technology has been set at $38. This reflects analysts' reactions to recent Q4 outperformance, higher long-term estimates, and ongoing attention to productivity, patient referrals, and the lymphedema business.TCMD: Lymphedema Momentum And Q4 Execution Will Support Multi Year Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to $38, reflecting a series of Street target increases into the $32 to $42 range, supported by recent Q4 outperformance, updated multi year guidance, and progress in productivity and cost controls. Analyst Commentary Street commentary around Tactile Systems Technology is mixed, with several bullish analysts lifting targets on the back of Q4 execution and longer term guidance, while more cautious voices question how much upside remains after the post earnings re rating.TCMD: Lymphedema Momentum And Q4 Execution Will Support Ongoing Upside Potential
Analysts have nudged their average price target for Tactile Systems Technology to $38. This reflects stronger recent Q4 execution, raised long term estimates and ongoing improvements in productivity, patient referrals and cost controls.TCMD: Lymphedema Momentum And Q4 Execution Will Support Measured Turnaround Expectations
The analyst fair value estimate for Tactile Systems Technology has been raised from $29.75 to $38.00, reflecting higher Street price targets in the $32 to $42 range as analysts cite recent Q4 upside, improved productivity and cost controls, and ongoing strength in the lymphedema business. Analyst Commentary Street research on Tactile Systems Technology is generally constructive, with higher fair value assumptions linked to recent Q4 performance, execution on productivity and cost controls, and expectations around the lymphedema business.TCMD: Index Inclusion And Stable Outlook Will Shape Measured Turnaround Expectations
Analysts have maintained their fair value estimate for Tactile Systems Technology at $29.75 per share. They cited only very small adjustments to assumptions regarding the discount rate, revenue growth, profit margins, and future P/E multiples, rather than any change in the core outlook.TCMD: Turnaround Momentum And Buyback Will Test Q3 Outperformance Sustainability
Analysts have raised their price targets on Tactile Systems Technology to a roughly mid to high $20s to low $30s range, citing stronger than expected Q3 results, improved productivity, sales force expansion, new products, and better reimbursement trends that together support a higher fair value assessment. Analyst Commentary Recent research points to a more constructive view on Tactile Systems Technology following its Q3 outperformance, with several firms raising price targets and upgrading ratings based on execution and perceived upside to fair value.TCMD: Q3 Turnaround Momentum And Buyback Will Face Execution Risk
Analysts have raised their price target on Tactile Systems Technology to about $29.75 from $24, citing stronger recent earnings performance, expectations for operational improvements, and support for a higher future P/E multiple. Analyst Commentary Recent research updates on Tactile Systems Technology highlight a clear shift toward a more constructive stance, with multiple firms lifting price targets after Q3 results and pointing to both execution progress and valuation support.Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 28%
Dec 18TCMD: Q3 Outperformance And Buyback Will Mask Limited Upside Ahead
Analysts have raised their price target on Tactile Systems Technology by about $8.50 to roughly $32 per share, citing significant Q3 outperformance, improving productivity and reimbursement trends, and expectations for a return to double digit growth by 2026. Analyst Commentary Recent research updates reflect a notably more constructive stance on Tactile Systems Technology, with bullish analysts pointing to operational momentum, clearer reimbursement visibility, and a sizable underpenetrated patient pool as key drivers of potential upside in the shares.TCMD: Q3 Outperformance And Buyback Plan Will Shape Turnaround Outlook
Analysts have raised their price expectations for Tactile Systems Technology toward the low to mid $30 range, citing a massive Q3 outperformance, consistent estimate beats, and growing confidence in a 2026 growth reacceleration and higher sustainable earnings power. Analyst Commentary Recent Street research reflects a broadly constructive stance on Tactile Systems Technology following its strong Q3 performance and improving fundamentals.TCMD: Sustained Product Execution And Buyback Plan Set To Shape Outlook
Analysts have raised their price target on Tactile Systems Technology significantly, from approximately $16.83 to $24.00. They cite strong quarterly outperformance and growing confidence in the company’s turnaround and future growth prospects.Results: Tactile Systems Technology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Nov 06TCMD: Market Leadership And Coverage Momentum Will Drive Expansion Into Underserved Patients
Narrative Update on Tactile Systems Technology Analysts have reaffirmed their price target for Tactile Systems Technology at $16.83 per share. They cite the company's leadership in key market segments and anticipated growth acceleration as a result of recent strategic improvements.At-home Healthcare And Workflow Automation Will Expand Patient Reach
Analysts have maintained their price target for Tactile Systems Technology at $23.50. They cite the company's leading positions in key device markets and an improved outlook following recent strategic adjustments.At-home Healthcare And Workflow Automation Will Expand Patient Reach
Analysts have raised their fair value estimate for Tactile Systems Technology from $13.50 to $16.83 per share. The change is attributed to optimism about the company's strengthened market leadership and the potential for renewed growth following recent strategic improvements.When Should You Buy Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Oct 04Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Shares Leap 28% Yet They're Still Not Telling The Full Story
Aug 29Tactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole Picture
May 12Slammed 28% Tactile Systems Technology, Inc. (NASDAQ:TCMD) Screens Well Here But There Might Be A Catch
May 08Why Tactile Systems Technology, Inc. (NASDAQ:TCMD) Could Be Worth Watching
May 07Tactile Systems Technology: Interesting Devices Company, Need More Clarity
Apr 07Tactile Systems Technology (NASDAQ:TCMD) Has A Rock Solid Balance Sheet
Feb 23Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 26%
Nov 25Tactile Systems Technology, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 07
Nimbl Approval And Tech Investments Propel Growth Amid Shrinking Margins And Operational Risks
Investments in technology and workflow improvements, alongside FDA approval for Nimbl, indicate a strong focus on innovation and market expansion.Investors Holding Back On Tactile Systems Technology, Inc. (NASDAQ:TCMD)
Jul 17US$20.67: That's What Analysts Think Tactile Systems Technology, Inc. (NASDAQ:TCMD) Is Worth After Its Latest Results
May 09Tactile Systems Technology, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 23Does Tactile Systems Technology (NASDAQ:TCMD) Have A Healthy Balance Sheet?
Oct 10Capital Allocation Trends At Tactile Systems Technology (NASDAQ:TCMD) Aren't Ideal
Sep 16Is It Time To Consider Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Jul 13Are Investors Undervaluing Tactile Systems Technology, Inc. (NASDAQ:TCMD) By 26%?
May 10Is Tactile Systems Technology (NASDAQ:TCMD) Using Too Much Debt?
Feb 16Aufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie Tactile Systems Technology Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 25 | 330 | 19 | 210 | 8 |
| 30 Sep 25 | 312 | 18 | 200 | 8 |
| 30 Jun 25 | 299 | 15 | 194 | 8 |
| 31 Mar 25 | 293 | 16 | 187 | 8 |
| 31 Dec 24 | 293 | 17 | 183 | 9 |
| 30 Sep 24 | 285 | 15 | 176 | 9 |
| 30 Jun 24 | 282 | 33 | 173 | 8 |
| 31 Mar 24 | 277 | 28 | 171 | 8 |
| 31 Dec 23 | 274 | 29 | 169 | 8 |
| 30 Sep 23 | 271 | 25 | 168 | 8 |
| 30 Jun 23 | 266 | 0 | 168 | 8 |
| 31 Mar 23 | 258 | -4 | 169 | 8 |
| 31 Dec 22 | 247 | -18 | 167 | 7 |
| 30 Sep 22 | 235 | -30 | 165 | 7 |
| 30 Jun 22 | 222 | -31 | 159 | 7 |
| 31 Mar 22 | 213 | -25 | 150 | 6 |
| 31 Dec 21 | 208 | -12 | 143 | 6 |
| 30 Sep 21 | 206 | 8 | 138 | 5 |
| 30 Jun 21 | 202 | 14 | 133 | 5 |
| 31 Mar 21 | 186 | -2 | 127 | 5 |
| 31 Dec 20 | 187 | -1 | 131 | 5 |
| 30 Sep 20 | 185 | -8 | 127 | 5 |
| 30 Jun 20 | 185 | -8 | 125 | 5 |
| 31 Mar 20 | 196 | 8 | 124 | 6 |
| 31 Dec 19 | 189 | 11 | 117 | 5 |
| 30 Sep 19 | 179 | 9 | 111 | 5 |
| 30 Jun 19 | 166 | 8 | 104 | 5 |
| 31 Mar 19 | 155 | 8 | 99 | 5 |
| 31 Dec 18 | 144 | 7 | 92 | 5 |
| 30 Sep 18 | 132 | 6 | 85 | 5 |
| 30 Jun 18 | 124 | 6 | 80 | 5 |
| 31 Mar 18 | 116 | 7 | 75 | 5 |
| 31 Dec 17 | 109 | 6 | 71 | 5 |
| 30 Sep 17 | 103 | 6 | 68 | 5 |
| 30 Jun 17 | 97 | 5 | 64 | 5 |
| 31 Mar 17 | 91 | 2 | 58 | 5 |
| 31 Dec 16 | 85 | 2 | 53 | 4 |
| 30 Sep 16 | 77 | 0 | 48 | 5 |
| 30 Jun 16 | 71 | 0 | 44 | 5 |
| 31 Mar 16 | 66 | -1 | 41 | 4 |
| 31 Dec 15 | 63 | 0 | 38 | 4 |
| 30 Sep 15 | 60 | 0 | 35 | 4 |
| 30 Jun 15 | 55 | 0 | 33 | 3 |
Qualität der Erträge: TCMD hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: TCMDDie aktuellen Gewinnspannen (5.8%) sind höher als im letzten Jahr (5.8%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: TCMD ist in den letzten 5 Jahren profitabel geworden und hat seinen Gewinn um 41.7% pro Jahr gesteigert.
Beschleunigtes Wachstum: TCMDDas Gewinnwachstum des Unternehmens im letzten Jahr (12.5%) liegt unter seinem 5-Jahres-Durchschnitt (41.7% pro Jahr).
Erträge im Vergleich zur Industrie: TCMD Das Gewinnwachstum im vergangenen Jahr (12.5%) übertraf das der Branche Medical Equipment 7.5% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: TCMDDie Eigenkapitalrendite des Unternehmens (8.7%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/04/30 08:04 |
| Aktienkurs zum Tagesende | 2026/04/29 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Tactile Systems Technology, Inc. wird von 12 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Argus Research Company |
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |